Combined anti-PD-1 and anti-CTLA-4 ICIs with palliative radiotherapy was found to be associated with few adverse events in patients with non-small cell lung cancer, melanoma, renal cell cancer, and breast cancer (192, 253). Here, CTLA4 is linked to breast carcinoma.